2021, Supplement 1
Cardiovasc Metab Sci 2021; 32 (S1)
First Mexican statement in Heart Failure
Magaña Serrano, José Antonio; Cigarroa López, José Ángel; Chávez Mendoza, Adolfo; Rayo Chávez, Jorge; Galván Oseguera, Héctor; Aguilera Mora, Luisa Fernanda; Ivey Miranda, Juan Betuel; Rascón Sabido, Rafael; Mendez Machado, Gustavo Francisco; Mendoza Zavala, Genaro Hiram; Olmos Dominguez, Luis; Chávez Leal, Sergio; Olalde Román, Marcos Jaciel; Fernández Muñoz, María de Jesús; Aceves García, Moisés; Pombo Bartelt, Ernesto; Pacheco Bouthillier, Alex Daniel; de León Larios, Gerardo; Coutiño,Hugo Enrique; Mariona Montero, Vitelio Augusto; González, Jorge; Hernández Rendón, Edgar; Álvarez San Gabriel, Amada; Álvarez Álvarez, Rolando Joel; Guízar Sánchez, Carlos Alberto; Araiza Garaygordobil, Diego; Herrera Garza, Eduardo Heberto; Castán Flores, David; Ruiz Ruiz, Vicente Eduardo; Tepayotl Aponte, Antonio; Gutiérrez Fajardo, Pedro; Borrayo Sánchez, Gabriela; Alcocer Gamba, Marco Antonio
ABSTRACT
I. Epidemiology, definition, etiology and classificationIn the United States and European Union countries, the prevalence of heart failure (HF) is close to 2% of the total adult population.1,2 With an incidence of more than 600 thousand new cases per year only in the United States. In addition, HF is the leading cause of hospitalization in people older than 65 years, with a poor prognosis and overall survival of 50% at five years after the diagnosis. In Mexico, there is a lack of a reliable National Registry to allow a precise knowledge of the size of this public health problem. This is relevant since cardiovascular diseases are the leading cause of death and disability in our country.